🎯 Clinical impact: ER-low BC should be managed more like TNBC, with inclusion in immunotherapy & ADC trials. Re-biopsy at relapse is crucial to detect phenotype switch.
#BreastCancer #ERlow #TNBC #Immunotherapy #Medicalwatch
aacrjournals.org/clincancerre...
#BreastCancer #ERlow #TNBC #Immunotherapy #Medicalwatch
aacrjournals.org/clincancerre...
Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial.
Abstract. Purpose: To assess prognosis of ER-low expression and its dynamics in HER2- metastatic breast cancer (BC) and to compare sensitivity to nivolumab between ER-low and triple-negative (TN) BC. ...
aacrjournals.org
September 8, 2025 at 2:55 PM
🎯 Clinical impact: ER-low BC should be managed more like TNBC, with inclusion in immunotherapy & ADC trials. Re-biopsy at relapse is crucial to detect phenotype switch.
#BreastCancer #ERlow #TNBC #Immunotherapy #Medicalwatch
aacrjournals.org/clincancerre...
#BreastCancer #ERlow #TNBC #Immunotherapy #Medicalwatch
aacrjournals.org/clincancerre...
Just talked about these results with 2 pts in 2 weeks. Improved outcomes with ET in ERlow breast cancer, unless pCR to Neoadj chemo. ascopubs.org/doi/10.1200/...
Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer
PURPOSEAdjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor
(ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those
with ER-low BC (ER 1%-10%)...
ascopubs.org
April 13, 2025 at 12:55 PM
Just talked about these results with 2 pts in 2 weeks. Improved outcomes with ET in ERlow breast cancer, unless pCR to Neoadj chemo. ascopubs.org/doi/10.1200/...